Subcutaneous Epcoritamab in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma: Preliminary Phase 1/2 Results

被引：0

作者：

Linton, Kim M. ^{[1
,2
]}

Wahlin, Bjorn ^{[3
,4
]}

Leppa, Sirpa ^{[5
]}

Morschhauser, Franck ^{[6
]}

Elliott, Brian ^{[7
]}

Liu, Tracy ^{[7
]}

Stirner, Mariana Cota ^{[8
]}

Abbas, Aqeel ^{[7
]}

Falchi, Lorenzo ^{[9
]}

机构：

[1] Christie NHS Fdn Trust, Manchester, Lancs, England

[2] Manchester Canc Res Ctr, Manchester, Lancs, England

[3] Karolinska Inst, Stockholm, Sweden

[4] Helsinki Univ Hosp, Ctr Comprehens Canc, Helsinki, Finland

[5] Univ Helsinki, Helsinki, Finland

[6] Univ Lille, CHU Lille, Lille, France

[7] Genmab, Princeton, NJ USA

[8] AbbVie, N Chicago, IL 60064 USA

[9] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2022年 / 197卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH22-PO53

引用

页码：94 / 94

页数：1

共 50 条

[1] Subcutaneous Epcoritamab in Combination with R 2 (Rituximab and Lenalidomide) in Patients with Relapsed or Refractory Follicular Lymphoma: Preliminary Results from a Phase 1/2 Trial
Linton, Kim M.
Wahlin, Bjorn
Leepa, Sirpa
Morschhauser, Franck
Elliot, Brian
Liu, Tracy
Stirner, Mariana Cota
Abbas, Aqeel
Falchi, Lorenzo
BLOOD, 2021, 138
[2] Subcutaneous Epcoritamab with Rituximab plus Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
Falchi, Lorenzo
Abrisqueta, Pau
Nijland, Marcel
Leppa, Sirpa
Hutchings, Martin
Holte, Harald
Merryman, Reid W.
Lugtenburg, Pieternella
de Vos, Sven
Cheah, Chan Y.
Christensen, Jacob Haaber
Arcaini, Luca
Drott, Kristina
Hellstrom, Mats
Leslie, Lori A.
Vitolo, Umberto
Rana, Ali
Abbas, Aqeel
Wang, Liwei
Minh Dinh
Belada, David
BLOOD, 2022, 140 : 1464 - 1466
[3] Subcutaneous Epcoritamab Combined With Rituximab plus Lenalidomide for the Treatment of Patients with Relapsed or Refractory Follicular Lymphoma: Phase 1/2 Trial Update
Lorenzo, Falchi
Sirpa, Leppa
Wahlin, Bjorn E.
Marcel, Nijland
Christensen, Jacob H.
De, Vos Sven
Harald, Holte
Linton, Kim M.
Aqeel, Abbas
Wang Liwei
Minh, Dinh
Brian, Elliott
David, Belada
AMERICAN JOURNAL OF HEMATOLOGY, 2022, 97 : S31 - S31
[4] EPCORE FL-1: Phase 3 Trial of Subcutaneous Epcoritamab with Rituximab and Lenalidomide (R 2) Vs R 2 Alone in Patients with Relapsed or Refractory Follicular Lymphoma
Falchi, Lorenzo
Morschhauser, Franck
Linton, Kim
Huang, Huiqiang
Galderisi, Faith
Quadri, Syed
Zeng, Lingmin
Hoehn, Daniela
Seymour, John F.
BLOOD, 2023, 142
[5] Subcutaneous Epcoritamab With Rituximab plus Lenalidomide (R2) in Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL): Update from Phase 1/2 Trial
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S392 - S392
[6] Phase 3 Trial of Subcutaneous Epcoritamab in Combination with Rituximab and Lenalidomide (R2) Vs R2 Among Patients with Relapsed or Refractory Follicular Lymphoma (EPCORE FL-1)
Falchi, Lorenzo
Morschhauser, Franck
Gribben, John G.
Huang, Huiqiang
Minh Dinh
Conlon, Rebekah
Chen, Xiaorong
Elliot, Brian
Seymour, John F.
BLOOD, 2022, 140 : 9338 - 9339
[7] Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1
Batlevi, Connie Lee
Salles, Gilles
Park, Steven, I
Phillips, Tycel J.
Amengual, Jennifer E.
Andorsky, David
Campbell, Philip
McKay, Pamela
Leonard, John P.
Sondhi, Manu
Chen, Yingxue
Slatcher, Pamela L.
Lin, Richard
Szanto, Attila
Abbadi, Sara
Morschhauser, Franck
BLOOD, 2022, 140 : 2296 - 2298
[8] Subcutaneous epcoritamab with rituximab plus lenalidomide (R2) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial.
Falchi, Lorenzo
Leppa, Sirpa
Wahlin, Bjorn E.
Nijland, Marcel
Christensen, Jacob Haaber
De Vos, Sven
Holte, Harald
Linton, Kim M.
Abbas, Aqeel
Wang, Liwei
Dinh, Minh
Elliott, Brian
Belada, David
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[9] Subcutaneous Epcoritamab in Combination with Rituximab plus Lenalidomide (R2) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
Falchi, Lorenzo
Leslie, Lori A.
Belada, David
Kopeckova, Katerina
Offner, Fritz
Brody, Joshua
Canales, Miguel
Martin Garcia-Sancho, Alejandro
Nijland, Marcel
Andersson, P-O
Awan, Farrukh T.
Christensen, Jacob Haaber
Drott, Kristina
Hellstrom, Mats
Lewerin, Catharina
Narkhede, Mayur
Snauwaert, Sylvia
Wahlin, Bjorn E.
Rana, Ali
Abbas, Aqeel
Wang, Liwei
Minh Dinh
Vermaat, Joost S. P.
Abrisqueta, Pau
BLOOD, 2022, 140 : 1471 - 1473
[10] Epcoritamab in Relapsed/ Refractory Follicular Lymphoma
Phillips, Tycel
ONCOLOGY-NEW YORK, 2024, 38 (08):

← 1 2 3 4 5 →